Furthermore, it remains unclear if chronically enhancing the activity of the PINK1-Parkin pathway may represent a therapeutic option for sporadic PD cases, as suggested by the neuprotective effects of Parkin overexpression on neurons exposed to α-synuclein toxicity (Lo Bianco et al., 2004b; Yasuda et al., 2007). Here, PRKN is linked to Parkinson disease.